Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account
when exercising their clinical judgment, as well as in the determination and the …

After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive review was conducted on literature published through March 1, 2020. Searches …

Aim This executive summary of the valvular heart disease guideline provides
recommendations for clinicians to diagnose and manage valvular heart disease as well as …

Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account
when exercising their clinical judgment, as well as in the determination and the …

Background: Nonrheumatic valvular diseases are common; however, no studies have
estimated their global or national burden. As part of the Global Burden of Disease Study …

Background: Post-market surveillance is needed to evaluate the real-world clinical
effectiveness and safety of US Food and Drug Administration–approved devices. Objectives …

In 2014, a joint consensus document dealing with the management of antithrombotic therapy
in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or …

Aims Significant efforts are currently undertaken to reduce functional mitral regurgitation
(FMR) in patients with chronic heart failure in the hope to improve prognosis. We aimed to …

Mitral regurgitation (MR) is a complex valve lesion that can pose significant management
challenges. This expert consensus decision pathway emphasizes that recognition of MR …